Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Current Treatment Landscape in First-line Urothelial Cancer

Meet the global experts featured in this video and then review the latest data and treatment algorithms informing first-line treatment of advanced urothelial cancer with immune checkpoint inhibitor–based regimens.
person default
Thomas Powles, MBBS, MRCP, MD
Alain Ravaud, MD, PhD
Released: October 15, 2020

This program is divided into several short segments which you can step through using the Video Chapters widget.
PreviousNext

Information on this Educational Activity

Faculty

Thomas Powles, MBBS, MRCP, MD

Deputy Centre Lead
Centre for Experimental Cancer Medicine
Barts Cancer Institute
Queen Mary University of London
Professor of Urology Cancer
Director of Barts Cancer Centre
Department of Cancer
St Bartholomew's Hospital (Barts Health NHS Trust)
London, United Kingdom

Thomas Powles, MBBS, MRCP, MD, has disclosed that he has received consulting fees from Astellas, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Incyte, Ipsen, Johnson & Johnson, Merck/MSD, Merck Serono, Novartis, Pfizer, Roche, and Seattle Genetics; funds for research support from Astellas, AstraZeneca, Bristol-Myers Squibb, Eisai, Exelixis, Ipsen, Johnson & Johnson, Merck/MSD, Merck Serono, Novartis, Pfizer, Roche, and Seattle Genetics; and other financial or material support from AstraZeneca, Ipsen, MSD, Pfizer, and Roche.
Alain Ravaud, MD, PhD

Professor of Medical Oncology
Bordeaux University
Head of Medical Oncology
Department of Medical Oncology
Bordeaux University Hospital,
Bordeaux, France

Alain Ravaud, MD, PhD, has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Ipsen, Merck, MSD, Novartis, Pfizer, and Roche.

Staff

Justine Stanley

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Target Audience

This targeted program is designed to both inspire and instruct urologists, medical oncologists, and other healthcare providers caring for patients with urothelial cancer (UC) around the world and especially in Europe (Big 5 EU and Switzerland) and South America (Argentina). The identified target audience will benefit from this education by gaining the knowledge necessary to integrate the use of immune checkpoint inhibitors (ICI) into the treatment of advanced UC.

Goal

The goal of this activity is to improve the competence and performance of learners to apply practice-changing clinical data and expert recommendations to optimize the use of the current and evolving immuno-oncology–based standard of care, first-line treatments, and sequencing in the care of their patients with urothelial cancer.

Program Medium

This program has been made available online.

Related Content

From Clinical Care Options (CCO), watch video featuring expert perspectives on the use of immunotherapy for HCC

Lipika Goyal, MD Amit G. Singal, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: November 24, 2020 Expired: November 23, 2021

Commentary by Heather McArthur, MD: clinical implications of FDA approval for pembrolizumab plus chemotherapy in PD-L1–positive advanced TNBC from CCO

Heather McArthur, MD, MPH Released: November 20, 2020

Matthew Galsky, MD, discusses the evolving use of immunotherapy in urothelial carcinoma, from Clinical Care Options (CCO)

Matthew Galsky, MD Released: November 19, 2020

In slides from Clinical Care Options (CCO), experts provide insights on the optimal treatment of advanced HCC

Mark Yarchoan, MD Released: November 19, 2020

Video Chapters


Supported by an educational grant from
Pfizer and EMD Serono, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue